Edgewise Therapeutics, Inc. EWTX Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s business segments — net income loss?
- Edgewise Therapeutics, Inc. (EWTX) reported business segments — net income loss of -$49.01M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s business segments — net income loss changed year-over-year?
- Edgewise Therapeutics, Inc.'s business segments — net income loss decreased by 20.1% year-over-year, from -$40.8M to -$49.01M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — net income loss?
- Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — net income loss has grown at a 29.4% compound annual growth rate (CAGR), from -$100.16M to -$167.8M.
- What does business segments — net income loss mean?
- Represents the bottom-line financial performance of the company after accounting for all revenues, operating expenses, and non-operating items. It provides a comprehensive view of the company's total profitability or loss for the period. This is the ultimate metric for assessing the overall financial impact of the company's business model on shareholder equity.